In pandemic lesson, German drug maker Stada banks on China for raw materials, supply chain security

Stada Arzneimittel, a German drug maker owned by private equity firms Bain Capital and Cinven, is turning to China to strengthen its global supply security while enhancing its presence in Asia’s biggest pharmaceutical market.The company is seeking partnerships to source more raw materials from the mainland as an insurance, an official said. Disruptions caused by the coronavirus pandemic since January have raised awareness among global drug manufacturers on the importance of health care supply…

Read the original article at South China Morning Post